

Analyze data from a variety of sources.

Tap Into Our Statistical Expertise

Our large team of biostatisticians is experienced in both observational studies and clinical trials, bringing a unique perspective to problem-solving in epidemiology and outcomes research.

The statisticians are key members of projects with data coming from patient registries, electronic medical records, surveys, and clinical trial databases.

- Our statisticians ensure that study plans and data collection will support study objectives.
- Because we work with all types of data in minute detail, we give you a better understanding of data nuances that can impact study findings.
- Using appropriate statistical methods provides key findings, which the statistician interprets for the given audience.

If you already have data available, our statisticians can be engaged directly to plan and perform exploratory analyses providing new insights from existing evidence.

- You may want to determine predictors of response, delineate subgroups, evaluate maintenance therapy, or examine correlations among endpoints.
- For example, application of the Q-TWiST method to oncology studies assesses whether adverse effects are offset by efficacy gains.
- For many products, quality-of-life improvements can be shown to accompany clinical outcomes.
- We also conduct meta-analyses based on published data or by pooling data across multiple clinical trials.

With extensive experience in multiple therapeutic areas, analytic techniques, and study types, we provide analyses that are trusted for solid decision-making.

Our Systematic Approach:



Our Statistical Services Include:

- Statistical consulting and representation to regulatory authorities
- Statistical input to protocols
- Development and implementation of statistical analysis plans (SAPs)
- Sample size calculation and randomization
- Meta-analysis/meta-regression including mixed treatment comparisons (MTC)
- Outcomes research such as analyses of quality-of-life data and health care resource utilization
- Analysis of data from:
 - Clinical trials (protocol-specified or post hoc)
 - Observational studies
 - Patient registries and medical records
 - Physician and patient surveys
- Statistical programming/validation/documentation
- Report writing and publication support

Contact Us:
info@rtihs.org
www.rtihs.org

Key Technical Staff

Beth Sherrill, MS

Vice President, Biostatistics
bsherrill@rti.org

Dawn Odom, MS

Global Head, Biostatistics
dodom@rti.org

Rely On Our Technical Team

Our statisticians and statistical programmers:

- Select state-of-the-art analytical methodologies based on project goals and data characteristics.
- Implement complex analytical techniques including mixed models, pattern-mixture, propensity scoring, sample weighting, multiple imputation, and survival techniques.
- Transform EDC data in various formats (e.g., CDISC).

- Plan programming suitable for the study purpose using GCP-compliant SOPs/ documentation when needed and providing high-quality, auditable tables.
- Propose additional analyses where suitable to make the most of your data.

We focus on thoughtful planning, attention to detail, and quality deliverables. This results in faster development of supplementary evidence for meeting regulatory requirements and creating value messages.

Selected Publications

Sherrill B, Fernandez MM, Wang J, Xin Y, Kwong WJ, Sherif BN, Hogue SL. Network meta-analysis of relative efficacy and safety of edoxaban versus other novel oral anticoagulants (NOACs) among atrial fibrillation patients with CHADS2 score greater than or equal to 2. Poster presented at American College of Cardiology; Mar 16, 2015. San Diego, CA.

Chang J, **Odom DM, Radder CN,** Kappeler C, Xu R, Qin S, Kim T, Li J. A post-hoc health-related quality of life (HRQoL) analysis of patients with metastatic colorectal cancer (mCRC) in the phase III CONCUR trial. Poster presented at ASCO Gastrointestinal Cancers Symposium; Jan 15, 2015. San Francisco, CA.

Wang J, Dong J, Hechmati G, Maglinte GA, Rong A, Barber BL, Douillard JY. Quality-adjusted survival in patients with RAS wild-type (WT) metastatic colorectal cancer (mCRC) receiving first-line therapy with panitumumab plus FOLFOX versus FOLXFOX alone in the PRIME trial. Poster presented at American Society of Clinical Oncology Gastrointestinal Cancers Symposium; Jan 15, 2015. San Francisco, CA.

Casulo C, Byrtek M, Dawson K, **Zhou X,** Flowers C, Farber C, Hainsworth J, Cerhan J, Link B, Friedberg J. Disease characteristics, treatment patterns, and outcomes of follicular lymphoma in patients 40 years of age and younger: an analysis from the National LymphoCare Study. Poster presented at the 56th ASH Annual Meeting and Exposition; Dec 7, 2014. San Francisco, CA.

Nastoupil LJ, Sinha R, Byrtek M, **Ziemięcki R,** Taylor M, Friedberg JW, Koff JL, Link BK, Cerhan JR, Dawson KL, Flowers CR. Comparison of the effectiveness of frontline chemoimmunotherapy regimens for follicular lymphoma used in the United States. *Leuk Lymphoma.* 2014 Nov 5;1-8.